Europe
Opening ceremony of new high-tech facility for the aseptic filling and freeze-drying of drug products.
Overall response rate at 28 days of 60%, complete response rate of 50%
Immunicum AB announced today that it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate its lead product, ilixadencel, an off-the-shelf cell-based cancer immune primer, in combination with avelumab*, a human anti-PD-L1 monoclonal antibody, in a planned multi-indication Phase Ib/II clinical trial.
NOXXON ends the use of variable rate equity financing with Yorkville
Thomas Eldered, CEO and co-founder of Recipharm AB, has informed the Company that he has sold 1,559,125 Class B shares in Recipharm, representing approximately 12.7% of his total shareholding in the Company, to a Swedish institutional investor.
How can a doctor predict the treatment outcome of an individual patient? Traditionally, the effectiveness of medical treatments is studied by randomised trials where patients are randomly divided into two groups: one of the groups is given treatment, and the other a placebo.
The highly successful twenty-fourth annual BIO-Europe® international partnering conference wrapped up in Copenhagen, Denmark, last week with a record-breaking 4,200+ attendees from the life sciences who engaged in over 26,000 one-to-one partnering meetings vying for 3,145 licensing opportunities on offer.
The highly successful twenty-fourth annual BIO-Europe(R) international partnering conference wrapped up in Copenhagen, Denmark, last week with a record-breaking 4,200+ attendees from the life sciences who engaged in over 26,000 one-to-one partnering meetings vying for 3,145 licensing opportunities on offer.
Positive outcomes from second Phase 1 trial with intranasal betahistine
Sareum Holdings plc has today reported new preclinical data that support its ongoing clinical trial with SRA737 as a monotherapy in ovarian cancer.
PRESS RELEASES